How Roche Tweaked an Aging Drug to Keep Profits Rolling In – Bloomberg

How Roche Tweaked an Aging Drug to Keep Profits Rolling In – Bloomberg

I blogged about this months ago. What’s amazing and messed up is I couldn’t get my insurance to pay for Rituxan forcing me to go on to Ocrevus when it cost so much more. I thank my stepmom for sending this to me this morning. It makes no difference but shows how the big business of the pharmaceutical world works. Is it ever only about the disease…

 

https://www.bloomberg.com/news/articles/2017-08-23/how-roche-tweaked-an-aging-drug-to-keep-profits-rolling-in?cmpId=flipboard

Ocrelizumab versus Rituximab (Rituxan)

4 thoughts on “How Roche Tweaked an Aging Drug to Keep Profits Rolling In – Bloomberg

  1. I hate big pharma. Always about profit. They r in our doctors offices and have one of the largest influences on our polital stage as well.

Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: